NEXT GENERATION DRUG FOR PARKINSON DISEASE

Around 6 million people are suffering from Parkinson disease worldwide. ; In the US, cost is about $23 billion per year. There is no cure, actual treatments are helping relieve the symptoms and maintain in certain level the patient quality of life : L-DOPA/ DOPA agonists ; COMT & MAO inhibitors have lack of efficiency and significant side effects. LRRK2 phosphorylation has an important effect in PD pathogenesis. We propose a new therapeutic peptides which targets PP1/ LRRK2 interaction, allowing the manipulation of PP1 effect on LRRK2.

Applications

Parkinson’s Disease

Competitive advantages

• Less cost than a biological molecule such as mAb.
• Low toxicity due to the fact that degradation of a peptide generates amino acids.
• Low immunogenicity since the size of the peptide is short and, as a consequence, lower possibility of stimulate the immune system.
• Blood Brain Barrier (BBB) penetration due to the association of the interfering peptide to a shuttle that cross the BBB.

Intellectual property

Patent application filed on March 2019.

Keywords

Parkinson’s Disease - Interfering peptides - PP1 - LRRK2 - Cell penetrating and interfering peptides